483
Intas Pharmaceuticals LimitedFDA 483 - Intas Pharmaceuticals Limited - July 31, 2017
Record Details
An FDA inspection of Intas Pharmaceuticals Limited in Ahmedabad, Gujarat, India, revealed a deficiency in sampling procedures for raw materials. Specifically, the firm's method for collecting composite samples from raw material containers was found to be inadequate. This indicates a potential issue with quality control and adherence to established sampling protocols.
Open in Dashboard
ID · 4f76e2d8-eaeb-4ac2-a891-807bdf0b6f08